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 Background: Cardioplegic arrest is a common procedure for many types of cardiac surgery, and different formulations have 
been proposed to enhance its cardio-protective effect. Hydrogen sulfide is an important signaling molecule 
that has cardio-protective properties. We therefore studied the cardio-protective effect of hydrogen sulfide in 
cardiac cell culture and its potential therapeutic use in combination with cardioplegia formulations.
 Materials/Methods: We added hydrogen sulfide donor GYY4137 to HL-1 cells to study its protective effect in nutrient starved con-
ditions. In addition, we tested the potential use of GYY4137 when it is added into two different cardioplegia 
formulations: Cardi-Braun® solution and del Nido solution in an ex vivo Langendorff perfused rat hearts model.
 Results: We observed that eight-hour pre-treatment with GYY4137 significantly suppressed apoptosis in nutrient-starved 
HL-1 cells (28% less compared to untreated cells; p<0.05), maintained ATP content, and reduced protein syn-
thesis. In ex vivo experiments, Cardi-Braun® and del Nido cardioplegia solutions supplemented with GYY4137 
significantly reduced the pro-apoptotic protein caspase-3 content and preserved ATP content. Furthermore, 
GYY4137 supplemented cardioplegia solutions decreased the S-(5-adenosyl)-L-methionine/S-(adenosyl)-L-
homocysteine ratio, reducing the oxidative stress in cardiac tissue. Finally, heart beating analysis revealed the 
preservation of the inter-beat interval and the heart rate in del Nido cardioplegia solution supplemented with 
GYY4137.
 Conclusions: GYY4137 preconditioning preserved energetic state during starved conditions, attenuating the cardiomyocytes 
apoptosis in vitro. The addition of GYY4137 to cardioplegia solutions prevented apoptosis, ATP consumption, 
and oxidative stress in perfused rat hearts, restoring its electrophysiological status after cardiac arrest. These 
findings suggested that GYY4137 sulfide donor may improve the cardioplegia solution performance during car-
diac surgery.
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Cardiovascular surgery requires interruption of coronary flow. 
However, restoration of blood flow to the heart after a signifi-
cant period of ischemia causes myocardial damage, a process 
known as reperfusion injury. Cardioplegia solutions attenuate 
such damage during surgical procedures [1], reducing reactive 
oxygen species (ROS) generation, oxygen consumption, and 
ATP depletion in the heart. Hyperkalemic cardioplegia formu-
lation is the most accepted strategy to preserve heart tissue 
during cardiac arrest. This procedure increases the extracellu-
lar potassium concentration [2], inducing cardiomyocytes de-
polarization and conferring a relative myocardial protection [3].
Many molecules have been described which may improve the 
cardioplegia solution performance. Hydrogen sulfide (H2S) is 
an endogenous gaseous mediator that exerts a broad range 
of physiological actions in mammalian tissues, such as partic-
ipating in cellular homeostasis and protecting cells from ne-
crosis, apoptosis, and oxidative stress [4,5]. In the heart, H2S 
has protective effects on myocardial ischemia-induced cell 
apoptosis [6,7], whereas its reduction in a cardiac injury mod-
el increases myocardial infarct size, suggesting a role for en-
dogenous H2S production in preventing myocardial ischemia 
injury [8]. Conversely, therapeutic delivery of H2S in a myo-
cardial ischemia model reduces the injury size, decreases the 
mortality rate, improves cardiac function, suppresses inflam-
mation, and attenuates fibrosis [9,10], suggesting a potential 
therapeutic role of the molecule in the heart.
Sodium hydrosulfide (NaHS) is the most common H2S-releasing 
drug used to evaluate the cardio-protective effects of exoge-
nous H2S in experimental models. However, rapid release of H2S 
in aqueous media has been observed, which does not mimic 
the physiological production of H2S in tissue [11]. In contrast, 
the controlled release of H2S from the GYY4137 sulfide donor 
drug has an important advantage to the study of their phys-
iological effects in tissue [12]. In aqueous solution at physio-
logical temperature and pH, the release of H2S from GYY4137 
is slow (4% to 5% H2S at 1 mmol/L in 25 minutes) and does 
not cause significant cytotoxic effect [11]. GYY4137 adminis-
tration has been associated with vasodilation and anti-hyper-
tensor activity in rats, whereas no effect has been observed in 
the cardiac function of health hearts [11].
Given this information, we tested the hypothesis that GYY4137 
modulates metabolism and reduces oxidative stress in cells, 
protecting cardiomyocytes from death induced by nutrient 
starvation, which could contribute to improve performance of 
cardioplegia solutions during cardiac arrest. GYY4137 protects 
HL-1 cardiomyocytes from death by nutrient starvation and 
safeguards ATP content and protein synthesis. Furthermore, 
the addition of GYY4137 to cardioplegia solutions in isolated 
Langendorff-perfused rat hearts preserved the energy state of 
the heart and promoted a reduction in apoptosis and oxida-
tive stress levels. Therefore, the slow H2S releaser GYY4137 is 
a potential molecule to preserve explanted tissue/organ dur-
ing ex vivo situations.
Material and Methods
Animals
Adult male Wistar rats (300–350 g) were purchased from 
Charles River Laboratories Inc. (Wilmington, MA, USA). All 
procedures were carried out in accordance with the Spanish 
Regulations for the Protection of Experimental Animals (R.D. 
1201/2005; B.O.E. 21.10.2005) and were approved by institu-
tional ethical and animal care committees.
Cell culture
HL-1 cell line, an atrial cardiac muscle cell line from the AT-1 
mouse, was purchased from the ATCC (Rockville, MD, USA). 
Cells were cultured in complete Claycomb® medium (Sigma-
Aldrich, Madrid, Spain) containing 10% fetal bovine serum 
(FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, 1 mM 
sodium pyruvate, and 0.1 mM norepinephrine. GYY4137 was 
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA, USA; sc-224013). For GYY4137 preconditioning, HL-1 cells 
were incubated overnight in complete Claycomb medium with 
300 µM GYY4137 or the equivalent concentration of inactive 
GYY4137; after which, the medium was replaced with one of 
the following experimental treatments: 1) complete Claycomb 
medium as nutrient complete medium [13] (formula is proprie-
tary to SigmaAldrich); 2) Krebs-Henseleit (KH) medium (118.4 
mM NaCl, 4.75 mM KCl, 1.19 mM KH2PO4, 2.54 mM MgSO4, 
2.44 mM CaCl2·2H2O, 28.6 mM NaHCO3, 10 mM glucose, and 10 
mM Hepes, pH 7.4) which established a medium without ami-
no acids but with glucose, mimicking a slight nutrient starva-
tion; 3) KH without glucose to simulate stress induced by nu-
trient deprivation (-Glu KH); or 4) PBS to simulate an extreme 
nutrient deprivation in cells. All experimental treatments were 
supplemented or not as appropriate with 300 µM GYY4137 and 
all cultures were incubated at 37ºC with 5% of CO2. To inacti-
vate GYY4137, the control group was heated for two hours at 
90 ºC and stored for one week at room temperature. Release 
of H2S from GYY4137 in vitro is both temperature and pH de-
pendent, with limited generation on ice (4 °C) with enhanced 
release with heating, as described in Li et al. [11].
Apoptosis assessment
HL-1 cells were preconditioned or treated with GYY4137 as de-
scribed. The pro-apoptotic drugs staurosporine (20 nM) and 
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doxorubicin (20 µM) were added to the treatments to deter-
mine whether GYY4137 protected not only by nutrient star-
vation but also by toxins in HL-1 cells. Apoptotic cells were 
identified by double-positive staining for recombinant fluores-
cein isothiocyanate (FITC)-conjugated annexin-V and propid-
ium iodide using the Annexin-V-FITC Apoptosis Detection Kit 
(BD Biosciences, Franklin Lakes, NJ, USA). Flow data acquisition 
and analysis was carried out on a Beckman Coulter FC500 MCL 
Flow Cytometer (Beckman Coulter, Brea, CA, USA).
Western blotting
HL-1 cells were seeded at 200,000 cells/well in a 6-well plate. 
At the end of treatment, cells were collected, washed with 
PBS, and lysed with RIPA buffer supplemented with a prote-
ase inhibitor cocktail (Roche Diagnostics GmbH, Mannhein, 
Germany). For ex vivo experiments, frozen ventricular heart tis-
sue was homogenized in the same lysis buffer with a Polytron 
homogenizer. Cells and homogenized tissue were centrifuged 
at 15,000 g at 4ºC for 15 minutes and the protein supernatant 
was collected. Twenty-five micrograms of protein lysate were 
loaded onto each lane of a 4–12% Bis-Tris gel (NuPAGENovex, 
Invitrogen, Carlsbad, CA, USA). Following electrophoresis, gels 
were transferred to PVDF membranes, blocked in 5% non-fat 
milk diluted in PBS and then incubated with anti-caspase-3, 
anti-PARP (both at 1: 1,000; Cell Signaling Technology, Danvers, 
MA, USA), anti-b-tubulin or anti-actin (both at 1: 1,000; Abcam, 
Cambridge, UK) overnight at 4ºC. After several washes, the 
membranes were incubated with appropriate anti-mouse or 
anti-rabbit horseradish peroxidase-conjugated secondary an-
tibodies (1: 10,000; Invitrogen) for one hour at room temper-
ature with shaking. Membranes were treated with luminol re-
agent (ECL; Pierce, Rockford, IL, USA) and exposed to x-ray film.
Nascent protein assay
Protein synthesis was measured in cells by methionine in-
corporation. Briefly, cells were first cultured for one hour in 
Dulbecco’s modified Eagle´s medium without methionine (Life 
Technologies, Paisley, UK), containing 10% FBS, 100 U/mL pen-
icillin, 100 μg/mL streptomycin, and 1 mM sodium pyruvate. 
Subsequently, cells were pulsed for three hours with the methi-
onine analogue L-azidohomoalanine (AHA) (Invitrogen; c10102) 
under various treatments with 300 µM of active or inactive 
GYY4137. As a control, cycloheximide (actidione, Sigma-Aldrich) 
was used to inhibit protein synthesis. After treatments, cells 
were homogenized in PBS buffer containing 1% SDS and pro-
tease inhibitors (Roche) and an aliquot of the lysate was taken 
for a ligation reaction between the azide-containing AHA incor-
porated into nascent proteins and biotin alkyne (PEG4 carbox-
amide-Propargyl Biotin) (Invitrogen; B10185) using the Click-
iT protein reaction buffer kit (Invitrogen; 10276). A dot-blot 
system was used to transfer the proteins onto a nitrocellulose 
membrane. Various controls were established to test the ex-
perimental system as follows: a negative control with non-bi-
otinylated AHA, a positive control using growing HL-1 cells in 
complete Claycomb medium, a no-analogue control (without 
AHA incorporation), and an actidione control comprising HL-1 
cells in Claycomb medium pre-treated with cycloheximde.
ATP quantification
HL-1 cells were seeded in 12-well plates at 10,000 cells per 
well in complete Claycomb medium. Cells were preconditioned 
with GYY4137 over 12 hours and ATP content was analyzed 
periodically. To evaluate the cardio-protective effect of H2S 
during nutrient deprivation, HL-1 cells were preconditioned 
overnight with GYY4137 and the culture medium was then re-
placed with PBS to promote starvation. ATP content was an-
alyzed at various times. To measure ATP, cells were washed 
twice with PBS buffer and then lysed with the addition of so-
matic cell ATP releasing reagent (FLSAR, Sigma-Aldrich). The 
supernatant was collected and kept at –20ºC until analysis. 
ATP content was measured with the bioluminescent ATP so-
matic cells assay kit (FLASC, Sigma-Aldrich). Luminescence of 
triplicate samples was read on a VICTORTM X3 Multilabel Plate 
Reader (PerkinElmer) with a test wavelength of 570 nm. Rat 
hearts were explanted and stored at –80ºC for ATP quantifi-
cation with the colorimetric ATP Assay Kit (Abcam) following 
the manufacturer’s instructions. Briefly, tissue samples were 
homogenized in ATP assay buffer, deproteinized with 1 M per-
chloric acid, and ATP content was determined by absorbance 
at 570 nm. ATP levels from experimental samples were com-
pared to sham samples (explanted hearts without treatment).
Metabolite analysis
Frozen heart tissues (50–100 mg) were placed in 2-mL tubes 
containing CK14 ceramic beads (Precellys, France). Then, six 
volumes of N-ethyl maleimide (NEM) 50 mM in PBS were add-
ed per weight of sample (mL/g). Sample homogenization for 25 
seconds at 6,000 g at 4°C was repeated twice in a Precellys 24 
Dual system equipped with a Cryolys cooler, also from Precellys. 
Samples were centrifuged at 10,000 g for 5 minutes at 4°C 
and supernatants were transferred to clean tubes. Tissue ex-
traction was repeated using four volumes of PBS containing 
50 mM NEM. Finally, supernatants were pooled and stored at 
–80°C for further analysis. Ultra-performance liquid chroma-
tography coupled to tandem mass spectrometry (UPLC-MS/MS) 
was then used to determine the concentration of indirect bio-
markers of oxidative stress. Reduced glutathione (GSH), oxi-
dized glutathione (GSSG) [13], S-(5-adenosyl)-L-methionine 
(SAM), and S-(adenosyl)-L-homocysteine (SAH) were select-
ed as key markers to evaluate oxidative protein damage. The 
UPLC-MS/MS system consisted of a Waters Acquity UPLC 
System (Manchester, UK) coupled to a Waters Xevo TQ-S mass 
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spectrometer. Quantitative analysis was performed with Waters 
MassLynx 4.1 software. The analytical method has been de-
scribed elsewhere [14].
Perfusion of isolated hearts
The standard Langendorff system (Harvard Apparatus) was 
used to evaluate the effects of GYY4137 in cardioplegia solu-
tions. Wistar rats were heparinized (500 U/kg, i.p.) and then 
anesthetized with sodium thiopental (50 mg/kg, i.p.). The tho-
racic cavity was exposed and the heart was quickly excised 
and immediately immersed in ice-cold Krebs-Henseleit medi-
um (KH) (118.4 mM NaCl, 4.75 mM KCl, 1.19 mM KH2PO4, 2.54 
mM MgSO4, 2.44 mM CaCl2·2H2O, 28.6 mM NaHCO3, 10 mM 
glucose, and 10 mM Hepes, pH 7.4). The aorta was cannulat-
ed and a retrograde perfusion of the heart with oxygenated 
KH (95% O2 and 5% CO2) was performed at a constant flow of 
10 mL/min at 37 ºC during 15 minutes to stabilize beating. A 
pre-treatment pseudo-ECG was recorded to analyze basal elec-
trical activity. After stabilization, cardioplegic arrest solutions 
were administered by retrograde perfusion (15 mL/Kg at 10 
mL/minute) and the heart was then immersed for one hour in 
the cardioplegic solution at 18ºC (ischemic period). After car-
dioplegic arrest, retrograde perfusion of the heart was per-
formed in the Langendorff apparatus with KH for 30 minutes 
to monitor the recovery of spontaneous beating. During this 
time, a post-treatment pseudo-ECG was recorded to analyze 
the electrical activity after cardioplegic arrest. After reperfusion, 
hearts were dissected and samples were removed for analysis.
Cardioplegic solutions
We tested two cardioplegic solutions with different formula-
tion and administration protocols. Conventional cardioplegic 
solution (Cardi-Braun® maintenance solution for reperfusion) 
contained 8.756 mg/mL trometamol, 1.5840 mg/mL sodium 
citrate, 0.1976 mg/mL citric acid monohydrate, 0.1512 mg/mL 
sodium dihydrogen phosphate dihydrate, 1.796 mg/mL po-
tassium chloride, and 9.86 mg/mL sodium chloride (B-Braun 
Inc., Barcelona, Spain). Osmolarity was 646 mOsm/L. This so-
lution required one initial administration dose (15 mL/Kg at 10 
mL/minute) and a maintenance dose (5 mL/kg at 10 mL/min-
ute) every 20 minutes. The conventional cardioplegia solution 
was diluted with blood, in a 4: 1 ratio of blood: cardioplegia 
solution. In some experiments, GYY4137 (300 µM) was add-
ed to the conventional cardioplegia solution, (conventional + 
GYY4137), which was administered following the same proto-
col as that described for conventional cardioplegia.
Additionally, we used del Nido cardioplegia [3] (kindly donate 
by Hospital La Fe, Valencia, Spain). Del Nido cardioplegia solu-
tion contained 144 mg/mL sodium, 117 mg/mL chlorine, 29.2 
mg/mL potassium, 156 mg/mL magnesium (in mEq/L), 0.1227 
mg/mL lidocaine HCl, and 3.07 mg/mL mannitol. Del Nido car-
dioplegia required only one administration dose (15 mL/Kg at 
10 mL/minute). Del Nido cardioplegia solution was also dilut-
ed with blood, in a ratio of 1: 4 blood: cardioplegia solution. In 
some experiments, GYY4137 (300 µM) was added to the del 
Nido cardioplegia solution: (Nido + GYY4137), which was ad-
ministered following the same protocol as that described for 
del Nido cardioplegia. In total, four experimental groups were 
tested as follows: 1) conventional; 2) conventional + GYY4137; 
3) del Nido; and 4) del Nido + GYY4137.
Electrical measurement
Pseudo-electrocardiogram (ECG) recordings were acquired in 
isolated rat hearts utilizing a single lead stainless steel uni-
polar electrode located in the epicardial base surface,f near to 
the right ventricular outflow tract. Up to 15–30 minutes pseu-
do-ECG tracings were acquired at a 1 kHz sampling rate using 
a custom preconditioning and data acquisition workstation. 
Briefly, low-voltage unipolar pseudo-EGM signals were ampli-
fied, band-pass filtered between 1–300 Hz and digitized with 
12-bit resolution. Offline pseudo-ECG analysis of stored data 
was performed utilizing custom Matlab (The Mathworks Inc., 
Natick, MA, USA) scripts for pre-processing, visualization, and 
quantification of heart rate variability before and after con-
ditioning with cardioplegic solutions. After band-pass digital 
filtering between 0.5V 250 Hz, baseline wander was removed 
using a bidirectional forward-backward digital filtering strat-
egy. Finite differential methods and wavelet transform were 
used for fiducial point estimation. A total average of 4,639±802 
complexes was considered in each segment (N=48 rats). Heart 
rate was automatically quantified using custom scripts in 
Matlab R2010a.
Statistical analyses
Data are represented as mean ±SEM. Comparisons between two 
experimental conditions were performed by unpaired Student´s 
t-test. One-way ANOVA was used for multiple comparisons fol-
lowed by Bonferroni´s post hoc test for pairwise comparisons. 
Data analysis was performed with Excel (Microsoft Office) and 
statistical methods with SPSS software (IBM). Differences were 
considered statistically significant at p<0.05 with a 95% con-
fidence interval (CI).
Results
Hydrogen sulfide preconditioning reduces cardiomyocyte 
apoptosis induced by nutrient deprivation
Cardioplegic arrest is a metabolism stress situation for the 
heart. To investigate whether H2S protects cardiomyocytes 
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from apoptosis induced by a stress situation as such nutrient 
deprivation using an in vitro approach, confluent HL-1 cells 
were preconditioned for eight hours with the slow-releasing 
H2S donor GYY4137 (300 µM) or an equivalent amount of in-
active GYY4137. After this period, the medium was replaced 
with KH medium with or without (-Glu KH) glucose, or with 
complete Claycomb medium supplemented with staurosporine 
(20 nM) or doxorubicin (20 µM), and apoptosis was evaluat-
ed at different time intervals by flow cytometry. In both -Glu 
KH (Figure 1A) and KH (Figure 1B) medium, the percentage 
of apoptosis was lower in cells preconditioned (pre-treated) 
with active GYY4137 than in cells preconditioned with inac-
tive GYY4137. By contrast, GYY4137 had no effect on cellu-
lar apoptosis induced by staurosporine (Figure 1C) or doxo-
rubicin (Figure 1D) in Claycomb medium, indicating that the 
protection mediated by GYY4137 was related to an adapta-
tion against metabolic stress/starvation rather than protec-
tion against cardiotoxic molecules. Furthermore, when HL-1 
cells were incubated in -Glu KH medium and treated direct-
ly with GYY4137, without preconditioning for eight hour, no 
protection from apoptosis was detected (Figure 1E), suggest-
ing that preconditioning with H2S was essential to reduce 
apoptosis. To corroborate these results, we measured the rel-
ative amount of the apoptosis markers cleaved poly (ADP-
ribose) polymerase (PARP) and caspase-3 in cells by Western 
blotting. Cells preconditioned with active GYY4137 had low-
er levels of cleaved PARP and caspase-3 than those precon-
ditioned with inactive GYY4137, both in KH and -Glu KH me-
dium (Figure 1F), which is consistent with protection against 
starvation-induced apoptosis.
H2S reduced cellular ATP levels and protein synthesis 
during preconditioning and attenuated their decay after 
starvation
Cell survival is dependent on the preservation of cellular bio-
energetics. To determine whether H2S influences cellular me-
tabolism, cellular ATP content was measured in HL-1 cells cul-
tured in Claycomb medium and preconditioned with GYY4137 
for different lengths of time. ATP content was significantly low-
er in cells treated for 30 minutes with active GYY4137 than in 
cells treated with inactive GYY4137 (Figure 2A) and continued 
to decrease over a period of two hours, after which time it re-
mained constant at approximately 50% of its original level. By 
contrast, ATP levels in cells treated with inactive GYY4137 re-
mained at approximately 80% of their original levels through-
out the time course (Figure 2A). Since protein turnover is an 
ATP-requiring metabolic process, we measured protein syn-
thesis during GYY4137 preconditioning. After a preincubation 
step without methionine, HL-1 cells were pulsed for three hours 
with the azide-containing amino acid AHA in the presence of 
active or inactive GYY4137 and protein synthesis was mea-
sured using Click-iT chemistry. Protein synthesis was lower in 
active GYY4137-treated cells than in cells treated with inactive 
GYY4137 as assayed by AHA incorporation (Figure 2B), suggest-
ing that H2S treatment reduces protein synthesis in HL-1 cells.
We next analyzed ATP levels in starvation conditions. When 
HL-1 cells were pre-treated for eight hours with active or inac-
tive GYY4137 and then starved in PBS, the initial ATP content 
in active GYY4127-treated cells was significantly lower than 
in cells treated with inactive GYY4137; however, the decline 
in ATP content was more rapid in inactive GYY4137-treated 
cells after 30 minutes of starvation (Figure 2C). Furthermore, 
after one hour and three hours of starvation, ATP levels in in-
active GYY4137-treated cells were lower than in the active 
GYY4137-treated group (Figure 2C). We also examined the ef-
fects of GYY4137 for protein synthesis during nutrient starva-
tion. Consistent with the results of ATP analysis, HL-1 cells pre-
treated with active GYY4137 had a lower incorporation of AHA 
than inactive GYY4137-treated cells after 30 minutes, but after 
one hour and three hours of starvation a dramatic reduction in 
AHA incorporation was observed in inactive GYY4137-treated 
cells, while cells treated with active GYY4137 maintained their 
incorporation of AHA (Figure 2D). Collectively, these results in-
dicate that GYY4137 promotes the preservation of ATP con-
tent and protein synthesis at basal levels.
H2S reduced myocardial apoptosis and preserved ATP 
levels in isolated hearts
Having demonstrated the metabolic cardio-protective proper-
ties of GYY4137 against stress induced by nutrient deprivation 
in cultured cells, we next evaluated the impact of GYY4137 in 
two cardioplegic solutions currently used in clinical practice: 
conventional Cardi-Braun® (Conv) and del Nido cardioplegia 
(Nido). The cardio-protective effect of GYY4137 was evaluat-
ed in isolated rat hearts secured to a Langendorff apparatus 
through the aorta. The scheme of the procedure is shown in 
Figure 3A and is described in materials and methods section. 
After the procedure, heart tissue was analyzed for the apop-
totic marker caspase-3. Western blotting showed that the 
levels of cleaved caspase-3 were significantly lower in heart 
tissue from GYY4137-supplemented groups than non-supple-
mented groups, both in Conv and Nido cardioplegic solutions 
(Figure 3B). Furthermore, we compared the relative activated 
caspase-3 content in Nido and Conv cardioplegia solutions 
supplemented with GYY4137 to determine which protected 
apoptosis more efficiently (left panel in Figure 3B). We ob-
served that hearts perfused with Nido + GYY4137 significantly 
reduced the activated caspase-3 amount compared to hearts 
perfused with Conv + GYY4137. Additionally, myocardial ATP 
levels were significantly higher when cardioplegic solutions 
were supplemented with GYY4137 (Figure 3C).
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H2S modulated oxidative stress levels in isolated hearts
We next analyzed oxidative stress (OS) levels in heart tissue 
after cardioplegic arrest and reperfusion. Since free radicals, 
such as ROS, are short-lived and therefore difficult to detect, 
an alternative strategy to assess OS is to evaluate the extent 
of injury triggered by their production. We therefore analyzed 
ROS production by measuring the presence of its oxidation 
target products. We measured the ratio of reduced glutathi-





































































































Figure 1.  Effect of GYY4137 on HL-1 cell apoptosis. (A) Effect of GYY4137 preconditioning on apoptosis of cells cultured in glucose and 
amino acid deprivation medium (-Glu KH). (B) Effect of GYY4137 preconditioning on apoptosis of cells cultured in amino acid 
deprivation medium (KH). (C, D) Effect of GYY4137 preconditioning on apoptosis of cells treated with staurosporine (C) and 
doxorubicin (D). (E) Effect of GYY4137 on apoptosis of cells during starvation in -Glu KH medium without preconditioning. In 
all cases, results show percentage of apoptosis over time. Dashed lines represent cells treated with active GYY4137 and solid 
lines represent cells treated with inactive GYY4137. Three replicates in three differences experiments were performed per 
condition. * p<0.05, ** p<0.01 GYY4137 preconditioning compared to control for each time. (F) Western blotting for apoptotic 
markers (PARP and caspases-3) in preconditioned HL-1 cells with active (+) or inactive (–) GYY4137, cultured in complete 
Claycomb medium (CM), KH or -Glu KH medium. Actin was used as a loading control.
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ratio of S-(5-adenosyl)-L-methionine (SAM) and S-(adenosyl)-
L-homocysteine (SAH) in hearts perfused with Conv or Nido, 
with or without supplemented GYY4137 (Figure 4). SAM is a 
precursor of GSH and an increase in the SAM/SAH ratio has 
been reported in cultured human lung cells exposed to high 
concentrations of peroxides [15]. The GSH/GSSG ratio in heart 
samples was increased when GYY4137 was added to either 
Conv or Nido cardioplegia solutions, and this was significant 
for Conv (Figure 4A). Moreover, the SAM/SAH ratio in both 
cardioplegic solutions was significantly decreased by supple-
mentation with GYY4137, validating the protection against 
OS (Figure 4B). These results suggest that H2S exerts a pro-
































































Figure 2.  Effect of GYY4137 on ATP content and protein synthesis in HL-1 cells. (A) Relative ATP content during preconditioning. ATP 
content is represented as relative content to non-preconditioned cells (0 hour). Dashed line represents cells treated with 
active GYY4137 and solid line represents cells treated with the inactive GYY4137. (B) Top panel, dot blot assay showing 
methionine L-azidohomoalanine (AHA) incorporation at 3 hours of preconditioning. Bottom panel, experimental set up for 
AHA incorporation: Negative control, non-biotinylated AHA; positive control, exponential cell growth in complete Claycomb 
medium; no analogue, biotinylation of extract without AHA incorporation; actidione, exponential cell growth in complete 
Claycomb medium after pre-treatment with the protein synthesis inhibitor cycloheximide. (C) Relative ATP content during 
nutrient starvation. ATP content is represented as relative content to the initial level of control cells (0 hour). Dashed line 
represents cells treated with active GYY4137 and solid line represents cells treated with inactive GYY4137. (D) Dot blot assay 
showing AHA incorporation at 30 minutes (0.5 hours), 1 hour, and 3 hours after starvation. * p<0.05, ** p<0.01 GYY4137 
preconditioning compared to control for each time. Triplicates were performed for each experiment (n=4).
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Figure 3.  GYY4137 improves cardioplegic cardio-protective performance during cardiac arrest. (A) Scheme of the procedure to test 
cardioplegic solutions in rat hearts utilizing a Langendorff apparatus. (B) Western blotting for caspase-3 in rat heart tissues 
perfused with Conv or del Nido cardioplegic solutions with or without GYY4137 (n=4). The graph shows quantification of 
densitometry analysis utilizing ImageJ software. (C) ATP quantification in rat heart tissue after finalization of Langendorff 
perfusion protocol as described in methods section. For the sham group, rat hearts were not subjected to the experimental 
Langendorff protocol; the organs were directly explanted and ATP content was analyzed. * p<0.05, ** p<0.01. Four hearts 
were used for each experimental group.
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Short-term recovery of cardiac rhythm and reduction of 
beat-to-beat variability by H2S
We registered electrical activation from the epicardial right ven-
tricular base before (PRE) and after (POST) cardioplegic condi-
tioning (Figure 5A). The overall mean cardiac frequency before 
treatment (N=48) was 244.31±3 0.41 bpm and was on aver-
age 8–25% lower after treatment across groups (Figure 5B). 
Cardiac activation of untreated hearts maintained in cold KH 
solution was lower (193.55±11.22 bpm, n=9) (Table 1). Neither 
treatment with Conv (n=10) nor ‘Conv + GYY4137’ (n=10) car-
dioplegia contributed to maintain cardiac activation since the 
post cardiac rate was significantly different to that of bas-
al conditions (251.07±11.23 and 241.01±1 0.49 bpm versus 
190.21±14.99 and 197.07±13.35 bpm for pre and post con-
ditioning, respectively), although the data trend pointed to a 
better recovery with GYY4137-supplemented cardioplegia so-
lution. By contrast, whereas the results for Nido cardioplegia 
solution alone were similar to those for Conv cardioplegia so-
lution, ‘Nido + GYY4137’ conditioning preserved regular car-
diac activation as shown by the non-significant change in car-
diac rate after treatment (231.61±7.08 versus 212.85±7.87 
bpm), indicating a prevention of short or mid-term decline 
in cardiac rate.
Discussion
Several studies have reported modulatory effects of H2S in di-
verse cellular process of cardiomyocytes, such as mitochon-
dria function, ROS production, or apoptosis. These actions are 
particularly highlighted during pathological process where 
hydrogen sulfide results in a cardio-protective response that 
preserves cardiac function [7,16,17]. In the present study, we 
showed that GYY4137 preconditioning in HL-1 cardiomyo-
cytes bring under nutrient deprivation attenuated apoptosis, 
demonstrating the cell protective effect of H2S in such condi-
tions. Moreover, the reduction of ATP and protein synthesis 
observed in cells could underlay the mechanism of protection. 
In concordance, the addition of GYY4137 sulfide donor into 
two distinct cardioplegia solutions reduced apoptosis and pre-
served ATP levels in rat hearts after cardiac arrest which likely 
induced the recovery of cardiac rhythm and beat-to-beat vari-
ability observed in the reperfused hearts.
Hydrogen sulfide preconditioning reduced cardiomyocyte apop-
tosis induced by nutrient deprivation (Figure 1). By contrast, 
no effect on cellular apoptosis induced by staurosporine or 
doxorubicin was observed, suggesting that GYY4137 protec-
tion was probably related to an adaptation against metabolic 
stress/starvation. This potential metabolic protection is likely 
mediated by optimization of general metabolism under stress 
situation. The reduction of protein synthesis during precon-
ditioning reduces ATP decay after starvation (Figure 2), pre-
serving ATP levels in isolated hearts (Figure 3) and contribut-
ing to myocardial apoptosis reduction.
There is evidence that H2S may affect cardiac mitochondria 
by reversible inhibition of cytochrome C oxidase, leading to a 
preservation of mitochondrial function [18]. In addition, H2S 
has been described as a stress inductor molecule that can re-
duce the energy requirements of cells [19]. Therefore, it is con-
ceivable that GYY4137 preconditioning prepares the cells for 
subsequent starvation period through reducing cellular ener-
getic requirements (Figure 2A, 2B). We observed beneficial ef-
fects of GYY4137 supplementation in global heart metabolism 
in two different cardioplegia solutions that, we presume, wasw 
related to lower energetic requirements in cells maintained in 
GYY4137-supplemented cardioplegia. Furthermore, its protec-
tive effect was reflected in the reduction of apoptosis and ox-
idative stress after the ischemic period (Figures 3, 4, respec-
tively). Interestingly, a positive role for H2S has been reported 
in ischemic preconditioning (IP) [20], in which endogenous H2S 
contributed to cardio-protection induced by IP through protein 
kinase C and sarcolemmal ATP potassium-dependent channels 
activity. Moreover, exogenous H2S administration also promotes 
Figure 4.  GYY4137 reduces oxidative stress during cardiac arrest. (A) Levels of oxidative stress biomarkers GSH, GSSG; and (B) SAM 
and SAH were analyzed in rat hearts treated with Conv or del Nido cardioplegia solutions with or without GYY4137. Graphs 
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cardio-protection in ischemia/reperfusion (I/R) models by in-
hibition of the sarcoplasmic reticulum oxidative stress [21], 
suggesting a similar effect that endogenous H2S. These re-
sults support our hypothesis that GYY4137-supplemented car-
dioplegia solution may improve cardiac performance via pro-











Nido + GYY4137 
(n=10)
Pre-treatment
Inter-beat interval (ms) 248.48±10.02 238.96±10.88 248.95±9.84 253.61±17.25 259.05±8.71
Heart rate (bpm) 241.46±9.20 251.07±11.23 241.01±10.49 236.58±11.58 231.61±7.08
Post-treatment
Inter-beat interval (ms) 309.99±15.99 315.43±27.08 304.45±23.10 292.77±16.73 281.88±10.74
Heart rate (bpm) 193.55±11.22 190.21±14.99 197.07±13.35 204.93±10.04 212.85±7.87
p value (inter-beat interval) 
Pre vs. Post
p=0.0017 p<0.001 p=0.003 p=0.021 p=0.17
p value (heart rate)
Pre vs. Post
p<0.001 p<0.001 p<0.001 p=0.003 p=0.08
Table 1. Analysis of electrical measurement in isolated working hearts.
Quantification of cardiac parameters extracted from volume-conducted pseudo-ECG electrical recordings in the isolated Langendorff-
perfused rat heart model. One-way ANOVA and Bonferroni post-test were used to compare pre- and post-treatment. n – number of 
hearts used for each treatment.
Figure 5.  Short-term electrical recovery after GYY4137 treatment in the isolated Langendorff-perfused rat model. (A) Representative 
5 second volume-conducted pseudo-ECG traces showing pre-treatment (Pre, light) or post-treatment (Post, dark) with 
cardioplegic solutions. A better preservation of heart rate (HR) and more regular cardiac activation is detected with del 
Nido+GYY4137 formulation than with untreated KH solution-preserved hearts. Traces are segmented after 15 minutes of 
registration from a single-lead electrode located at the epicardial base of the right ventricle in the Langendorff-perfused 
whole-heart. (B) Quantification of the effects of cardioplegic treatment on heart rate (HR, beats per minute) reveals 
significant slowing of cardiac activation, whereas heartrate-slowing is non-significantly different in the del Nido + GYY4137 


































Cardiac rhythm and beat-to-beat variability were restored in 
reperfused hearts (Figure 5, Table 1). It has been shown that 
GYY4137 does not alter the electrical or functional properties 
in healthy perfused rat hearts [11]. In contrast, its administra-
tion reduces the scar size and preserves cardiac function and 
structure after myocardial infarction [22], suggesting that its 
cardio-protective effect is only manifested during pathologi-
cal process. Therefore, these findings suggest that GYY4137 
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administration reduces the cardiac injury induced by the re-
perfusion process in our model, which results in the restoring 
the electrophysiological status of the heart.
In summary, H2S preconditioning promotes a starvation-like 
state in normal conditions, preparing the cell for a low ener-
getic requirement state. Such effect reduces apoptosis and ox-
idative stress in cardiomyocytes during nutrient deprivation 
conditions, improving the heart status after cardiac arrest. 
Further studies are warranted to test the molecular mecha-
nism underlying to the metabolic decay induced by H2S pre-
conditioning in this model.
We acknowledge some limitations of our work. Although we 
showed the protective effect of H2S in starved HL-1, more ex-
periments are needed to reproduce the conditions of the ex 
vivo experiments in this work. Langendorff system allows us to 
take data on left ventricular pressures. In this work, for tech-
nical reasons, we could not take such measures that would 
have been of interest for the study.
Conclusions
In this work, we demonstrated that GYY4137 sulfide donor 
preconditioning reduces ATP levels and protein synthesis in 
cardiomyocytes, attenuating their decay and apoptosis of cells 
during nutrient deprivation conditions. Furthermore, the addi-
tion of GYY4137 to cardioplegic performance solutions reduc-
es apoptosis, increases ATP levels, and prevents redox mole-
cules oxidation in rat hearts after cardiac arrest, promoting the 
recovery of cardiac rhythm and beat-to-beat variability after 
their reperfusion. Further studies are required to test the po-
tential therapeutic use of GYY4137 in cardioplegia solutions.
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